Spero Therapeutics Inc (SPRO)

Feb 06, 2025

Spero Therapeutics Inc (SPRO)’s results reveal risk - US Post News

Feb 06, 2025

Feb 06, 2025

Spero therapeutics director Ankit Mahadevia sells $53,990 in stock By Investing.com - Investing.com Australia

Feb 06, 2025

Feb 06, 2025

Spero Therapeutics CEO sells shares worth $121,159 - MSN

Feb 06, 2025

Feb 05, 2025

Spero therapeutics CFO sells $16,137 in stock - Investing.com India

Feb 05, 2025

Feb 05, 2025

Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN

Feb 05, 2025

Feb 05, 2025

Spero therapeutics director Ankit Mahadevia sells $53,990 in stock - Investing.com India

Feb 05, 2025

Feb 05, 2025

Spero Therapeutics Inc (SPRO) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Feb 05, 2025

Feb 05, 2025

An Analysis of Spero Therapeutics Inc (SPRO)’s Potential Price Growth - Knox Daily

Feb 05, 2025

Feb 05, 2025

Stock Market Recap: Spero Therapeutics Inc (SPRO) Concludes at 0.75, a -6.19 Surge/Decline - The Dwinnex

Feb 05, 2025

Feb 04, 2025

Spero Therapeutics, Inc. (NASDAQ:SPRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough - Simply Wall St

Feb 04, 2025

Feb 02, 2025

Spero Therapeutics’ (SPRO) Buy Rating Reiterated at HC Wainwright - Defense World

Feb 02, 2025

Jan 30, 2025

The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts - Benzinga

Jan 30, 2025

Jan 21, 2025

Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World

Jan 21, 2025

Jan 19, 2025

Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal (NASDAQ:SPRO) - Seeking Alpha

Jan 19, 2025

Jan 16, 2025

Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know - MSN

Jan 16, 2025

Jan 16, 2025

Spero Therapeutics stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa

Jan 16, 2025

Jan 15, 2025

Spero Therapeutics stock hits 52-week low at $0.92 - Investing.com India

Jan 15, 2025

Jan 15, 2025

TD Cowen Downgrades Spero Therapeutics (SPRO) - MSN

Jan 15, 2025

Jan 14, 2025

Thinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin? - Marketscreener.com

Jan 14, 2025

Jan 12, 2025

Geode Capital Management LLC Decreases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jan 12, 2025

Jan 12, 2025

Spero Therapeutics Discloses Financial Estimates and Leadership Changes Amid SEC InvestigationOn January 7, 2025, Spero Therapeutics, Inc. (NASDAQ: SPRO) released a significant update and disclosed estimated financial information as of December 3 - Defense World

Jan 12, 2025

Jan 10, 2025

Spero Therapeutics, Inc. Announces CEO Changes - Marketscreener.com

Jan 10, 2025

Jan 10, 2025

Spero Therapeutics announces interim leadership amid SEC inquiry - Investing.com India

Jan 10, 2025

Jan 10, 2025

Spero Therapeutics announces interim leadership changes - TipRanks

Jan 10, 2025

Jan 10, 2025

Spero Therapeutics Faces SEC Probe and Leadership Changes - TipRanks

Jan 10, 2025

Jan 10, 2025

Spero Therapeutics names Esther Rajavelu as Interim President and CEO (NASDAQ:SPRO) - Seeking Alpha

Jan 10, 2025

Jan 10, 2025

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes - GlobeNewswire

Jan 10, 2025

Dec 28, 2024

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat

Dec 28, 2024

Dec 23, 2024

Spero Therapeutics (NASDAQ:SPRO) Cut to In-Line at Evercore ISI - Defense World

Dec 23, 2024

Dec 20, 2024

Evercore ISI Group Downgrades Spero Therapeutics (SPRO) - MSN

Dec 20, 2024

Dec 20, 2024

Spero Therapeutics (NASDAQ:SPRO) Lowered to In-Line Rating by Evercore ISI - MarketBeat

Dec 20, 2024

Dec 20, 2024

What 4 Analyst Ratings Have To Say About Spero Therapeutics - Benzinga

Dec 20, 2024

Dec 16, 2024

Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Dec 16, 2024

Dec 13, 2024

Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat

Dec 13, 2024

Dec 04, 2024

Research Analysts Set Expectations for SPRO FY2024 Earnings - MarketBeat

Dec 04, 2024

Dec 04, 2024

Spero Therapeutics Q3 2024 Earnings Preview - MSN

Dec 04, 2024

Dec 02, 2024

Wainwright reiterates Buy rating on Spero Therapeutics with PIVOT-PO enrolment on track - Investing.com Canada

Dec 02, 2024

Nov 26, 2024

Carbapenem Market Size, Trends, Growth, Opportunities - openPR

Nov 26, 2024

Nov 20, 2024

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 20, 2024

Nov 20, 2024

TD Cowen Reaffirms “Hold” Rating for Spero Therapeutics (NASDAQ:SPRO) - Defense World

Nov 20, 2024

Nov 19, 2024

Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World

Nov 19, 2024

Nov 18, 2024

Spero Therapeutics' (SPRO) "Hold" Rating Reiterated at TD Cowen - MarketBeat

Nov 18, 2024

Nov 17, 2024

Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 17, 2024

Nov 16, 2024

Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 16, 2024

Nov 15, 2024

Spero Therapeutics (NASDAQ:SPRO) Given "Overweight" Rating at Cantor Fitzgerald - MarketBeat

Nov 15, 2024

Nov 15, 2024

Spero Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada

Nov 15, 2024

Nov 14, 2024

Spero Therapeutics Inc. (SPRO) Quarterly 10-Q Report - Quartzy

Nov 14, 2024